Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

3 Dividend Kings Delivering Generational Income & Market-Beating Returns

Not every stock needs a flashy growth story to outperform. Sometimes, the biggest winners are the companies that simply keep executing, quarter after quarter, year after year- it’s all about consistency.

In 2025, a handful of quiet standouts are doing precisely that, delivering substantial year-to-date gains while continuing to reward investors with reliable income. These are businesses with deep moats, disciplined management teams, and a proven ability to thrive across market cycles.

Fundamentals

See More
  • Market Capitalization, $K 497,206,208
  • Shares Outstanding, K 2,409,295
  • Annual Sales, $ 88,821 M
  • Annual Income, $ 14,066 M
  • EBIT $ 29,302 M
  • EBITDA $ 36,641 M
  • 60-Month Beta 0.36
  • Price/Sales 5.65
  • Price/Cash Flow 16.03
  • Price/Book 6.39

Options Overview Details

View History
  • Implied Volatility 19.37% (-0.34%)
  • Historical Volatility 18.02%
  • IV Percentile 73%
  • IV Rank 30.57%
  • IV High 35.15% on 04/08/25
  • IV Low 12.42% on 07/24/25
  • Expected Move (DTE 6) 2.94 (1.43%)
  • Put/Call Vol Ratio 0.50
  • Today's Volume 21,561
  • Volume Avg (30-Day) 35,733
  • Put/Call OI Ratio 0.98
  • Today's Open Interest 423,622
  • Open Int (30-Day) 403,535
  • Expected Range 203.43 to 209.31

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 2.53
  • Number of Estimates 8
  • High Estimate 2.57
  • Low Estimate 2.51
  • Prior Year 2.04
  • Growth Rate Est. (year over year) +24.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
199.90 +3.23%
on 12/09/25
215.18 -4.10%
on 12/15/25
+3.86 (+1.91%)
since 11/19/25
3-Month
174.12 +18.52%
on 09/22/25
215.18 -4.10%
on 12/15/25
+30.18 (+17.13%)
since 09/19/25
52-Week
140.68 +46.69%
on 01/10/25
215.18 -4.10%
on 12/15/25
+62.79 (+43.73%)
since 12/19/24

Most Recent Stories

More News
3 Dividend Kings Delivering Generational Income & Market-Beating Returns

3 top-performing Dividend Kings of 2025 based on their Year-to-Date percent change.

JNJ : 206.37 (-0.93%)
ABBV : 226.82 (+1.80%)
NUE : 159.15 (+0.84%)
Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma

-  TRUFILL n-BCA is now indicated for embolization of the middle meningeal artery (MMA) for the treatment of symptomatic subacute and Chronic Subdural Hematoma (cSDH) as an adjunct to surgery. ...

JNJ : 206.37 (-0.93%)
Rate Cuts Make These 3 Income ETFs More Attractive Than Ever

Low interest rates can give dividend stocks, real estate investment trusts, and corporate bonds a boost; these ETFs allow investors to capitalize.

VCIT : 83.64 (-0.17%)
KO : 70.06 (-0.43%)
JNJ : 206.37 (-0.93%)
VNQ : 88.59 (-0.38%)
VYM : 143.33 (+0.33%)
U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)

RYBREVANT FASPRO â„¢, the first and only subcutaneous therapy for patients with EGFR-mutated NSCLC, reduces administration time from hours to minutes and significantly reduces administration-related...

JNJ : 206.37 (-0.93%)
3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most

Healthcare behemoths, including the biggest name of them all, are increasing their dividends. Additionally, AMGN's dividend yield now sits solidly above 3%.

SYK : 355.20 (+0.59%)
JNJ : 206.37 (-0.93%)
LLY : 1,071.44 (+1.38%)
AMGN : 327.38 (+0.91%)
Pfizer Adds to Its Big Bet on Weight Loss Drugs

A month after acquiring obesity biotech Metsera, Pfizer's expanding in the weight loss drug market after signing a licensing agreement for a weight loss pill.

NVO : 48.09 (+1.01%)
JNJ : 206.37 (-0.93%)
LLY : 1,071.44 (+1.38%)
REGN : 767.96 (+2.57%)
PFE : 25.19 (+0.60%)
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results

Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, January 21 st to review fourth-quarter...

JNJ : 206.37 (-0.93%)
Jury says Johnson & Johnson owes $40 million to 2 cancer patients who used talcum powders

A Los Angeles jury has awarded $40 million to two women who claim Johnson & Johnson's talcum powder caused their ovarian cancer

JNJ : 206.37 (-0.93%)
U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*

Expanded indication for AKEEGA ® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine combination treatment for patients with...

JNJ : 206.37 (-0.93%)
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma

TECVAYLI ® and DARZALEX FASPRO ® combination led to a statistically significant progression-free survival and overall survival advantage compared to standard treatment after three years...

JNJ : 206.37 (-0.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 211.61
2nd Resistance Point 210.42
1st Resistance Point 208.40
Last Price 206.37
1st Support Level 205.19
2nd Support Level 204.00
3rd Support Level 201.98

See More

52-Week High 215.18
Last Price 206.37
Fibonacci 61.8% 186.72
Fibonacci 50% 177.93
Fibonacci 38.2% 169.14
52-Week Low 140.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar